^
Association details:
| Biomarker: | TLR8 overexpression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + motolimod (VTX 2337) (TLR8 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent
Published date:
01/15/2021
Excerpt:
...to examine the role of TLR8 expression/activity in head and neck squamous cell carcinoma (HNSCC) to facilitate the prediction of responders to VTX-2337-based therapy…The anti-tumor effects of VTX-2337+ cetuximab were accompanied by increased splenic lymphoid...patients with high TLR8 expression may be more likely to derive benefit from this drug combination compared to patients with low TLR8 expression.
DOI:
10.1038/s41598-020-80957-z
